<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref152">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Van Heeke</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Allosery</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>De Brabandere</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>De Smedt</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Detalle</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>De Fougerolles</surname>
    <given-names>A.</given-names>
   </name>
  </person-group> (
  <year>2017</year>). 
  <article-title>Nanobodies® as inhaled biotherapeutics for lung diseases</article-title>. 
  <source>Pharmacol. Ther.</source>
  <volume>169</volume>, 
  <fpage>47</fpage>–
  <lpage>56</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.pharmthera.2016.06.012</pub-id>, PMID: 
  <?supplied-pmid 27373507?>
  <pub-id pub-id-type="pmid">27373507</pub-id>
 </mixed-citation>
</ref>
